Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease
Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild...
Gespeichert in:
Veröffentlicht in: | Journal of thrombosis and haemostasis 2007-02, Vol.5 (2), p.282-288 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 288 |
---|---|
container_issue | 2 |
container_start_page | 282 |
container_title | Journal of thrombosis and haemostasis |
container_volume | 5 |
creator | BARONCIANI, L. FEDERICI, A. B. COZZI, G. CANCIANI, M. T. MANNUCCI, P. M. |
description | Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD. |
doi_str_mv | 10.1111/j.1538-7836.2007.02349.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68971841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68971841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</originalsourceid><addsrcrecordid>eNqNUcFu1DAQtRCIlsIvoDkhOGyw42TtHDi0FaWgSlwKPVqOMyZeJXGws90u_8d_4WQXkDjhi9943nsz8iMEGM1YOm83GSu5XAnJ11lOqchozosqe3hETv80Hv_GFecn5FmMG0pZVeb0KTlhgpVlVYhT8vPCedNi74zuwLQ6aDNhcD_05PwA3oKGgMb3tRv0MMF9erxzXYd10EMDNrF9gNdf767ewM5NLRyo2MC0HxHyC5hpC2bQoEUzRXADTC1CEsE3HHCpdx7GNBOH1F-M9NHhHMYWB78UaZ1_FmhcRB3xOXlidRfxxfE-I1-u3t9eXq9uPn_4eHl-szJ8LapVTQvOTclMURQls03OcyoTKNJX5FY0tDJWI7eyriQvqdC8trWsGG0amwvO-Rl5dfAdg_--xTip3kWDXacH9Nuo1rISTBYsEeWBaIKPMaBVY3C9DnvFqJojVBs1p6PmpNQcoVoiVA9J-vI4Y1v32PwVHjNLhHcHws51uP9vY_Xp9npG_BeMKqwE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68971841</pqid></control><display><type>article</type><title>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>BARONCIANI, L. ; FEDERICI, A. B. ; COZZI, G. ; CANCIANI, M. T. ; MANNUCCI, P. M.</creator><creatorcontrib>BARONCIANI, L. ; FEDERICI, A. B. ; COZZI, G. ; CANCIANI, M. T. ; MANNUCCI, P. M.</creatorcontrib><description>Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2007.02349.x</identifier><identifier>PMID: 17155947</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Collagen - metabolism ; Dimerization ; expression study ; Family Health ; Humans ; Male ; Middle Aged ; Mutation, Missense ; Pedigree ; Platelet Glycoprotein GPIb-IX Complex - metabolism ; Protein Binding ; Recombinant Proteins - genetics ; Siblings ; type 1 ; type 2A ; type 2B ; von Willebrand disease ; von Willebrand Diseases - classification ; von Willebrand Diseases - diagnosis ; von Willebrand Diseases - genetics ; von Willebrand Factor - genetics</subject><ispartof>Journal of thrombosis and haemostasis, 2007-02, Vol.5 (2), p.282-288</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</citedby><cites>FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17155947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARONCIANI, L.</creatorcontrib><creatorcontrib>FEDERICI, A. B.</creatorcontrib><creatorcontrib>COZZI, G.</creatorcontrib><creatorcontrib>CANCIANI, M. T.</creatorcontrib><creatorcontrib>MANNUCCI, P. M.</creatorcontrib><title>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD.</description><subject>Collagen - metabolism</subject><subject>Dimerization</subject><subject>expression study</subject><subject>Family Health</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation, Missense</subject><subject>Pedigree</subject><subject>Platelet Glycoprotein GPIb-IX Complex - metabolism</subject><subject>Protein Binding</subject><subject>Recombinant Proteins - genetics</subject><subject>Siblings</subject><subject>type 1</subject><subject>type 2A</subject><subject>type 2B</subject><subject>von Willebrand disease</subject><subject>von Willebrand Diseases - classification</subject><subject>von Willebrand Diseases - diagnosis</subject><subject>von Willebrand Diseases - genetics</subject><subject>von Willebrand Factor - genetics</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcFu1DAQtRCIlsIvoDkhOGyw42TtHDi0FaWgSlwKPVqOMyZeJXGws90u_8d_4WQXkDjhi9943nsz8iMEGM1YOm83GSu5XAnJ11lOqchozosqe3hETv80Hv_GFecn5FmMG0pZVeb0KTlhgpVlVYhT8vPCedNi74zuwLQ6aDNhcD_05PwA3oKGgMb3tRv0MMF9erxzXYd10EMDNrF9gNdf767ewM5NLRyo2MC0HxHyC5hpC2bQoEUzRXADTC1CEsE3HHCpdx7GNBOH1F-M9NHhHMYWB78UaZ1_FmhcRB3xOXlidRfxxfE-I1-u3t9eXq9uPn_4eHl-szJ8LapVTQvOTclMURQls03OcyoTKNJX5FY0tDJWI7eyriQvqdC8trWsGG0amwvO-Rl5dfAdg_--xTip3kWDXacH9Nuo1rISTBYsEeWBaIKPMaBVY3C9DnvFqJojVBs1p6PmpNQcoVoiVA9J-vI4Y1v32PwVHjNLhHcHws51uP9vY_Xp9npG_BeMKqwE</recordid><startdate>200702</startdate><enddate>200702</enddate><creator>BARONCIANI, L.</creator><creator>FEDERICI, A. B.</creator><creator>COZZI, G.</creator><creator>CANCIANI, M. T.</creator><creator>MANNUCCI, P. M.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200702</creationdate><title>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</title><author>BARONCIANI, L. ; FEDERICI, A. B. ; COZZI, G. ; CANCIANI, M. T. ; MANNUCCI, P. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Collagen - metabolism</topic><topic>Dimerization</topic><topic>expression study</topic><topic>Family Health</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation, Missense</topic><topic>Pedigree</topic><topic>Platelet Glycoprotein GPIb-IX Complex - metabolism</topic><topic>Protein Binding</topic><topic>Recombinant Proteins - genetics</topic><topic>Siblings</topic><topic>type 1</topic><topic>type 2A</topic><topic>type 2B</topic><topic>von Willebrand disease</topic><topic>von Willebrand Diseases - classification</topic><topic>von Willebrand Diseases - diagnosis</topic><topic>von Willebrand Diseases - genetics</topic><topic>von Willebrand Factor - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARONCIANI, L.</creatorcontrib><creatorcontrib>FEDERICI, A. B.</creatorcontrib><creatorcontrib>COZZI, G.</creatorcontrib><creatorcontrib>CANCIANI, M. T.</creatorcontrib><creatorcontrib>MANNUCCI, P. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARONCIANI, L.</au><au>FEDERICI, A. B.</au><au>COZZI, G.</au><au>CANCIANI, M. T.</au><au>MANNUCCI, P. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2007-02</date><risdate>2007</risdate><volume>5</volume><issue>2</issue><spage>282</spage><epage>288</epage><pages>282-288</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17155947</pmid><doi>10.1111/j.1538-7836.2007.02349.x</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1538-7933 |
ispartof | Journal of thrombosis and haemostasis, 2007-02, Vol.5 (2), p.282-288 |
issn | 1538-7933 1538-7836 1538-7836 |
language | eng |
recordid | cdi_proquest_miscellaneous_68971841 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Collagen - metabolism Dimerization expression study Family Health Humans Male Middle Aged Mutation, Missense Pedigree Platelet Glycoprotein GPIb-IX Complex - metabolism Protein Binding Recombinant Proteins - genetics Siblings type 1 type 2A type 2B von Willebrand disease von Willebrand Diseases - classification von Willebrand Diseases - diagnosis von Willebrand Diseases - genetics von Willebrand Factor - genetics |
title | Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biochemical%20characterization%20of%20a%20recombinant%20von%20Willebrand%20factor%20(VWF)%20with%20combined%20type%202B%20and%20type%201%20defects%20in%20the%20VWF%20gene%20in%20two%20patients%20with%20a%20type%202A%20phenotype%20of%20von%20Willebrand%20disease&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=BARONCIANI,%20L.&rft.date=2007-02&rft.volume=5&rft.issue=2&rft.spage=282&rft.epage=288&rft.pages=282-288&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2007.02349.x&rft_dat=%3Cproquest_cross%3E68971841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68971841&rft_id=info:pmid/17155947&rfr_iscdi=true |